Biotechnology Class 12 Biology NCERT Exemplar Solutions 2026-27

Correct option: (d) Resistant to all pesticides.

Concept used. Bt cotton is a transgenic crop that carries one or more cry genes (commonly cry1Ac or cry2Ab) borrowed from the soil bacterium Bacillus thuringiensis. The cry gene codes for a crystal protoxin that, once eaten by a lepidopteran larva (bollworm), is activated in the insect's alkaline midgut, binds gut epithelial receptors, and lyses the cells — killing the pest. Bt cotton is therefore (i) a GM plant, (ii) insect-resistant against specific groups (mainly lepidopterans), and (iii) a bacterial gene expressing system. It is not, however, resistant to all pesticides — pesticide tolerance is a different trait that requires herbicide-resistance genes (such as bar for glufosinate or epsps for glyphosate).

1. Check (a): a gene from B. thuringiensis has been inserted into the cotton genome — by definition, Bt cotton is a Genetically Modified (GM) plant. Option (a) is therefore TRUE of Bt cotton.
2. Check (b): the Cry toxin kills bollworms (Helicoverpa, Pectinophora), so Bt cotton is insect-resistant. Option (b) is TRUE.
3. Check (c): the inserted cry gene is bacterial in origin and is expressed in the plant tissues — making the plant a bacterial-gene expression system. Option (c) is TRUE.
4. Check (d): the Cry protein is selectively toxic to insects, not to herbicides or fungicides. Bt cotton is NOT resistant to pesticides as a class — that is a separate trait (e.g. Roundup Ready cotton uses the epsps gene). Option (d) is FALSE of Bt cotton, and since the question asks what Bt cotton is not, this is the correct choice.

Option (d) Resistant to all pesticides.

Correct option: (c) Removed during maturation of pro-insulin to insulin.

Concept used. Insulin is first synthesised by the β-cells of the pancreatic islets as a single long polypeptide called preproinsulin, which is processed into proinsulin after signal-peptide cleavage. Proinsulin is folded into a hairpin with three intra-chain disulphide links and contains three segments: the A-chain (21 residues), the B-chain (30 residues), and an internal C-peptide (connecting peptide) of ∼ 31 residues that joins A and B. The mature, biologically active hormone is generated when proteolytic enzymes excise the C-peptide, leaving only the A and B chains joined by disulphide bridges. The C-peptide itself does not appear in mature insulin.

1. Trace the biosynthesis pathway: Preproinsulin → Proinsulin → Insulin (A + B) + C-peptide. Proteases in the secretory granules cleave out the C-peptide.
2. Test option (a): C-peptide is removed before secretion, so it is not a part of mature insulin. (a) is FALSE.
3. Test option (b): the disulphide bridges connect specific cysteines in the A and B chains; they form via cysteine residues of A and B alone, not via the C-peptide. (b) is FALSE.
4. Test option (c): C-peptide is excised by prohormone-convertase enzymes during the maturation of proinsulin to insulin. (c) is TRUE.
5. Test option (d): biological activity (lowering blood glucose by binding the insulin receptor) is carried out by the A+B mature hormone; C-peptide has only minor signalling roles unrelated to glucose homeostasis. (d) is FALSE.

Option (c) Removed during maturation of pro-insulin to insulin.

Correct option: (c) Genetic Engineering Approval Committee.

Concept used. GEAC is the apex Indian regulatory body that sits under the Ministry of Environment, Forest and Climate Change. Its remit is to approve the use, large-scale production, and environmental release of Genetically Modified Organisms (GMOs) and products derived from them. It evaluates field trials of Bt crops, the import of GM foods, biosafety dossiers, and confined R&D on hazardous microorganisms. As of 2024 it has been renamed Genetic Engineering Appraisal Committee in policy documents, but NCERT continues to use the original full form ``Genetic Engineering Approval Committee''.

1. Recall the full form taught in NCERT: Genetic Engineering Approval Committee.
2. Compare with the options: (a) and (b) start with the wrong words (``Genome'', ``Ground''); (d) reverses ``Genetic and Environment'' which is not the body's title.
3. Only (c) matches the official NCERT expansion.

Option (c) Genetic Engineering Approval Committee.

Correct option: (d) Used to treat emphysema.

Concept used. α-1 antitrypsin (AAT) is a serine-protease inhibitor (not an enzyme) synthesised mainly in the liver and circulated in plasma. Its principal physiological role is to neutralise neutrophil elastase in the lungs, protecting alveolar walls from being digested by the body's own protease. A genetic deficiency of AAT leads to uninhibited elastase activity, alveolar destruction, and emphysema (a form of COPD). Therapeutic AAT — now produced commercially as a transgenic protein in milk of cattle and goats — is administered to AAT-deficient patients as augmentation therapy to slow emphysema progression.

1. Test (a): an antacid neutralises stomach acid (e.g. aluminium hydroxide). AAT does no such thing. FALSE.
2. Test (b): AAT is a protease inhibitor, not an enzyme. Enzymes catalyse reactions; inhibitors block enzymes. FALSE.
3. Test (c): arthritis treatment uses NSAIDs, DMARDs (methotrexate), biologics (anti-TNF). AAT plays no clinical role here. FALSE.
4. Test (d): AAT augmentation therapy is the standard treatment for hereditary AAT-deficiency emphysema. TRUE.

Option (d) Used to treat emphysema.

Correct option: (c) Either RNA or DNA.

Concept used. A molecular probe is a short, single-stranded nucleic acid carrying a detectable label (radioactive ³²P, biotin, fluorophore, or chemiluminescent tag) used to find a complementary target sequence by molecular hybridization. Because base-pairing is the same whether the partner is DNA or RNA (A–T, A–U, G–C), probes can be made of either single-stranded DNA (ssDNA, common in Southern blots and microarrays) or single-stranded RNA (ssRNA, common in Northern blots and in-situ hybridization, where it is called a riboprobe).

1. Recall the hybridization rule: complementary single-stranded sequences anneal via H-bonds (Watson–Crick base pairing). The chemistry does not care whether the probe backbone is DNA or RNA.
2. Practical examples — ssDNA probes: Southern blot, FISH (fluorescence in-situ hybridization), DNA microarrays. ssRNA (riboprobe) probes: Northern blot, in-situ mRNA detection.
3. Eliminate options: (a) only ssRNA — too restrictive; ssDNA probes are common. (b) only ssDNA — too restrictive; riboprobes exist. (d) ``not ssRNA'' contradicts the existence of riboprobes.
4. Only (c) — either RNA or DNA — covers the practice.

Option (c) Either RNA or DNA.

Correct option: (a) An RNA virus that synthesises DNA during infection.

Concept used. A retrovirus is an enveloped RNA virus whose genome is single-stranded positive-sense RNA. Inside the host cell, it carries (and packages) the enzyme reverse transcriptase (RNA-dependent DNA polymerase) that transcribes the viral RNA backwards into double-stranded DNA. This proviral DNA is then integrated into the host genome by another viral enzyme, integrase. The classic textbook example is HIV; another well-known retrovirus is the murine leukaemia virus (MLV) used as a gene-therapy vector.

1. Identify the genome: ssRNA(+).
2. Identify the unique enzyme: reverse transcriptase, which makes DNA from the RNA template (the retro step).
3. Identify the next step: integrase splices the cDNA into host DNA as a provirus; host RNA-polymerase then transcribes it to make new viral RNA and proteins.
4. Compare options: (b) describes the normal flow of DNA viruses; (c) and (d) misidentify the genome chemistry. Only (a) captures the retroviral hallmark.

Option (a) An RNA virus that synthesises DNA during infection.

Correct option: (b) Lymphocytes.

Concept used. Adenosine deaminase (ADA) is a purine-metabolism enzyme that breaks down toxic deoxyadenosine into deoxyinosine. While ADA is expressed in many tissues at low levels, its physiologically critical site is the lymphocyte (both B and T cells), where high ADA activity is essential for normal lymphocyte maturation and function. ADA deficiency therefore selectively cripples the immune system, producing the disease Severe Combined Immunodeficiency (SCID) — children with no working immunity, requiring sterile-bubble isolation or treatment by gene therapy / enzyme replacement / bone-marrow transplant.

1. Identify the enzyme: ADA = adenosine deaminase, part of the purine-salvage pathway.
2. Identify the dominant site: lymphocytes (T and B cells of the immune system) — they show the highest ADA activity in the body.
3. Eliminate distractors: erythrocytes have ADA but at lower levels; blood plasma is not a producing tissue (it is fluid); osteocytes are bone cells, unrelated to immunity.
4. Connect to disease: ADA-deficient lymphocytes cannot mature, hence SCID.

Option (b) Lymphocytes.

Correct option: (d) Inactive toxin.

Concept used. A protoxin is the inactive precursor form in which many microbial toxins are first synthesised. It carries the full toxin sequence plus an additional ``pro''-region whose presence blocks the toxic activity. Only after a specific physiological trigger — proteolytic cleavage, pH change, or interaction with a receptor — is the pro-region removed, generating the active toxin. The classical biotech example is the Cry protoxin of Bacillus thuringiensis: it is harmless inside the bacterium itself, but the alkaline pH of an insect's midgut (and gut proteases) cleaves it into the active toxin that perforates the insect-gut cell membrane.

1. Define the term: ``proto-'' = first / precursor. ``Protoxin'' = an early, inactive form of a toxin.
2. Mechanism of activation: limited proteolysis or chemical change releases the active toxin from the precursor.
3. Example: Bt Cry protoxin activated in the alkaline pH of the lepidopteran midgut.
4. Eliminate distractors: (a) ``primitive'' is wrong vocabulary; (b) denatured = damaged, also not the meaning; (c) protozoa are unrelated; (d) ``inactive toxin'' matches the precursor definition exactly.

Option (d) Inactive toxin.

Correct option: (c) Study of altered physiology of host.

Concept used. Pathophysiology (Greek pathos = suffering / disease + physiology) is the branch of medicine that studies the altered, abnormal functioning of a body, organ or cell that occurs as a result of a disease process. It bridges basic physiology (how things work normally) and clinical medicine (how to treat) by explaining the mechanisms by which a disease produces its symptoms and signs. For example, the pathophysiology of cystic fibrosis is the impaired chloride-channel function (CFTR mutation) that thickens airway mucus.

1. Decompose the word: patho- = disease + physio-logy = study of body functions.
2. Pick the matching option: physiology altered by disease in the host — option (c).
3. Eliminate distractors: (a) refers to microbial physiology; (b) is plain physiology, not pathophysiology; (d) is wrong since (c) is correct.

Option (c) Study of altered physiology of host.

Correct option: (c) Alkaline pH of gut.

Concept used. Bacillus thuringiensis (Bt) produces its Cry insecticidal protein as an inactive crystal protoxin. When an insect larva (typically a lepidopteran caterpillar) eats Bt-treated leaves, the protoxin enters the larva's midgut. Unlike the mammalian stomach (pH 1–3, strongly acidic), the lepidopteran midgut is strongly alkaline (pH 9–10.5). This alkaline environment solubilises the crystal and activates gut proteases that cleave the protoxin into the smaller, active Cry toxin. The active toxin then binds receptors on midgut epithelial cells, inserts into the membrane, forms pores, and lyses the cells — killing the larva. Because the human stomach is acidic, the protoxin is harmless to us.

1. Recall the Bt protoxin pathway: crystal protoxin alkaline gut + proteases active Cry toxin → binds midgut epithelium → pore formation → cell lysis.
2. Identify the activating environment: the lepidopteran midgut, which is alkaline (pH 9–10.5).
3. Eliminate distractors: (a) acidic stomach does not activate Cry — it would denature it; (b) temperature is not the trigger; (d) mechanical action does not chemically alter the protein.
4. Conclude: alkaline pH is the trigger — (c).

Option (c) Alkaline pH of gut.

Correct option: (c) A transgenic rice having gene for β-carotene.

Concept used. Golden rice is a biofortified transgenic rice engineered by Ingo Potrykus and Peter Beyer (1999, published 2000) to carry two genes — psy (phytoene synthase, from daffodil and later from maize) and crtI (carotene desaturase, from Erwinia uredovora) — that together complete the β-carotene biosynthetic pathway in rice endosperm. Wild rice grains are white because their endosperm cannot make β-carotene; the transgenic version accumulates β-carotene, giving the grains a yellow (``golden'') colour. Once eaten, β-carotene is converted in the human body into vitamin A, addressing the widespread vitamin-A deficiency (VAD) that causes childhood blindness and immune impairment in rice-staple countries.

1. Recall the engineering: two transgenes (psy + crtI) inserted to reconstitute the carotenoid pathway in endosperm.
2. Recall the phenotype: yellow-orange endosperm → ``golden'' colour from β-carotene.
3. Recall the purpose: dietary precursor of vitamin A; tackle VAD in rice-staple populations.
4. Eliminate distractors: (a) and (b) are geographic / storage misconceptions; (d) implies a wild type, but golden rice is engineered, not natural.

Option (c) A transgenic rice having gene for β-carotene.

Correct option: (c) ds RNA.

Concept used. RNA interference (RNAi) is a sequence-specific gene-silencing mechanism that responds to double-stranded RNA (dsRNA). When dsRNA enters or is produced in a cell, the enzyme Dicer (an RNase III) cleaves it into 21–23 nt small interfering RNAs (siRNAs). One strand of the siRNA is loaded onto the RISC complex (containing Argonaute), which uses it as a guide to find and either cleave or block translation of the complementary mRNA — silencing the gene. RNAi is exploited in biotechnology (e.g. engineering nematode-resistant tobacco by expressing dsRNA targeted at a parasite-essential transcript).

1. Identify the trigger: cells initiate RNAi only when they detect dsRNA (which, in animals, signals a viral infection).
2. Identify the processing: Dicer cleaves the dsRNA into 21–23 nt siRNA duplexes.
3. Identify the silencing step: one strand guides RISC to complementary mRNA, which is cleaved or translationally repressed.
4. Eliminate options: (a) ssDNA and (b) dsDNA do not trigger RNAi; (d) ssRNA includes mRNAs themselves, which are the targets, not the triggers. Only (c) dsRNA initiates the pathway.

Option (c) ds RNA.

Correct option: (d) SCID resulting from ADA deficiency.

Concept used. The first ever clinical gene therapy was performed in 1990 at the US NIH by W. French Anderson and Michael Blaese, on a four-year-old girl, Ashanthi DeSilva, suffering from ADA-SCID (Severe Combined Immunodeficiency caused by adenosine deaminase deficiency). Her own lymphocytes were extracted, transduced ex vivo with a retroviral vector carrying a functional copy of the human ADA gene, expanded in culture, and re-infused. Because mature lymphocytes have a finite life, the procedure had to be repeated periodically. The trial was a landmark proof-of-concept for gene therapy in humans.

1. Recall the patient: Ashanthi DeSilva, 1990.
2. Recall the disease: ADA-SCID — a genetic immunodeficiency caused by lack of functional ADA enzyme in lymphocytes.
3. Recall the procedure: ex-vivo retroviral transduction of patient lymphocytes with the wild-type ADA cDNA, re-infused.
4. Eliminate distractors: AIDS, cancer and cystic fibrosis are all important gene-therapy targets but were not the first clinical trial.

Option (d) SCID resulting from ADA deficiency.

Correct option: (b) Adenosine deaminase.

Concept used. Adenosine deaminase (ADA) is a purine-salvage enzyme that catalyses the irreversible hydrolytic deamination of adenosine (and deoxyadenosine) to inosine (and deoxyinosine): Adenosine + H₂O ADA enzyme Inosine + NH₃. When ADA is absent, deoxyadenosine accumulates and is phosphorylated to deoxyATP, which is selectively toxic to lymphocytes — producing SCID.

1. Recall the substrate–enzyme–product triad: adenosine → ADA → inosine + NH₃.
2. Recall the trivial name: ``adenosine deaminase'' (it deaminates adenosine).
3. Pick (b). Distractors swap adenosine for aspartate / arginine, or add a spurious ``deoxy''.

Option (b) Adenosine deaminase.

Correct option: (c) both RNAi and antisense RNA.

Concept used. Gene silencing — preventing a particular mRNA from being translated into protein — can be achieved by several RNA-based mechanisms. Two of the most prominent are:

• 2pt
• Antisense RNA — a single-stranded RNA complementary to the target mRNA. It base-pairs with the mRNA forming a dsRNA duplex that blocks ribosome binding (translational arrest) and/or recruits RNase H to cleave the RNA part of the duplex.
• RNA interference (RNAi) — uses dsRNA processed by Dicer into siRNA, which is loaded into RISC to cleave complementary mRNA.

1. Antisense RNA pairs with target mRNA, blocks translation, may recruit RNase H to cut the mRNA.
2. RNAi uses dsRNA → Dicer → siRNA → RISC → mRNA cleavage.
3. Both routes silence specific genes, so both work. Option (c).

Option (c) both RNAi and antisense RNA.

Concept used. The Green Revolution (1960s–70s) raised India's food-grain output by introducing semi-dwarf high-yielding wheat (Norman Borlaug's Mexican wheat) and IR-8 rice, combined with chemical fertilizers, pesticides, and irrigation. While it averted famine, the revolution's reliance on chemical inputs, monocultures, and water-intensive irrigation created lasting ecological and social problems.

1. Yield ceiling. Conventional high-yielding varieties have plateaued; further yield gain from breeding alone is small.
2. Chemical-input dependence. Heavy use of nitrogenous fertilizers leached into groundwater (nitrate pollution) and chemical pesticides killed pollinators, contaminated food chains and triggered pest resistance.
3. Soil degradation. Continuous monoculture depleted micronutrients, salinised soils (over-irrigation), and reduced organic matter.
4. Water depletion. Tube-well irrigation in Punjab and Haryana lowered the water table dramatically.
5. Loss of biodiversity. A few hybrid varieties displaced thousands of traditional landraces, narrowing the genetic base.
6. Regional inequity. Benefits concentrated in Punjab, Haryana and western UP; rain-fed regions and small farmers gained little.

The earlier Green Revolution gave India self-sufficiency but at the cost of chemical-input dependence, soil and water degradation, lost biodiversity, and regional inequity — limitations that biotechnology (GM crops, biofertilizers, biopesticides) is now expected to address.

Concept used. GMO stands for Genetically Modified Organism — an organism whose genome has been deliberately altered by inserting, deleting, or modifying specific DNA sequences using recombinant DNA technology, often introducing genes from different species. A hybrid, by contrast, is the offspring of conventional sexual cross-breeding between two genetically distinct individuals of the same species (or, rarely, closely related species), in which whole genomes blend by natural genetic recombination. The key contrasts are (i) the technique (rDNA vs. controlled crossing), (ii) cross-species movement of genes (yes vs. no), and (iii) precision (single targeted gene vs. thousands of genes shuffled).

1. Define GMO: organism with deliberately engineered DNA, typically a transgene from another species (e.g. Bt cotton with bacterial cry gene).
2. Define hybrid: progeny of sexual cross between two parents of the same species; whole genomes recombine naturally (e.g. hybrid maize from inbred parental lines).
3. Tabulate the difference: (a) GMO involves rDNA technology; hybrids do not. (b) GMO can carry genes from unrelated organisms; hybrids cannot cross sexual barriers. (c) GMO modifies one or a few genes precisely; hybrids shuffle the whole genome.

GMO = Genetically Modified Organism, made by inserting specific recombinant DNA across species barriers; a hybrid is the offspring of conventional sexual crossing within a species, with whole-genome shuffling.

Concept used. Diagnostics are procedures or products that detect or identify a disease or disease-causing agent in a patient, typically before treatment begins. Therapeutics are procedures or products that treat the disease once identified, by curing, controlling or alleviating it. Biotechnology has produced powerful tools in both categories: PCR and ELISA on the diagnostic side; recombinant insulin, monoclonal antibodies and gene therapy on the therapeutic side.

1. Define diagnostics: tools to detect / measure a disease or pathogen. Examples: PCR for HIV nucleic acid, ELISA for HIV antibody, lateral-flow rapid tests for COVID-19.
2. Define therapeutics: tools to treat or cure. Examples: recombinant human insulin (for diabetes), recombinant clotting factor VIII (for haemophilia A), Strimvelis gene therapy (for ADA-SCID).
3. Highlight one example of each: Diagnostic: ELISA for HIV. Therapeutic: recombinant human insulin (Humulin) for diabetes mellitus.

Diagnostics detect a disease; therapeutics treat it. Diagnostic example: ELISA for HIV. Therapeutic example: recombinant human insulin for diabetes.

Concept used. ELISA = Enzyme-Linked Immunosorbent Assay. It is a plate-based immunoassay used to detect and quantify antigens (e.g. a viral coat protein) or antibodies (e.g. host anti-viral antibodies) in a sample. Diseases routinely diagnosed by ELISA include HIV/AIDS, hepatitis B, dengue, rotavirus diarrhoea, COVID-19, and several autoimmune conditions. The principle is the specific binding of an antigen and its antibody, coupled to an enzyme that produces a coloured product whose intensity is proportional to the amount of bound analyte.

1. Coat the microtitre well with the capture molecule (antigen or antibody).
2. Add the patient sample. If the complementary partner is present, it binds.
3. Wash; then add an enzyme-linked secondary antibody that binds the captured molecule.
4. Add a substrate that the enzyme converts to a coloured product.
5. Measure colour intensity (absorbance) — proportional to the amount of analyte. A positive signal confirms the disease.

ELISA = Enzyme-Linked Immunosorbent Assay. It detects HIV (and many other diseases) by capturing the antigen or antibody on a plate, tagging it with an enzyme-linked antibody, and measuring colour produced by enzyme action on a substrate.

Concept used. Yes — early molecular diagnostics can detect a disease before the patient develops symptoms, by directly looking for the pathogen's nucleic acid (PCR) or for the host's immune response (ELISA, antibody tests) at concentrations far below those that cause clinical disease. The two pillars are:

• 2pt
• PCR (Polymerase Chain Reaction) — exponentially amplifies a few copies of pathogen DNA / cDNA to detectable levels, even when the pathogen load is too low to cause symptoms.
• ELISA — detects pathogen antigens or host antibodies; serum antibodies often appear before the disease becomes clinically apparent.

1. Principle: even one or a few molecules of pathogen DNA can be exponentially amplified by PCR and visualised, so detection precedes the symptomatic threshold.
2. Same principle for antibodies: a low (sub-clinical) infection still triggers detectable IgM / IgG, picked up by ELISA before symptoms.
3. For genetic diseases (e.g. cancer-predisposing mutations), molecular probes hybridise to the mutant allele in tissue or blood DNA before tumour formation.

Yes. PCR amplifies tiny amounts of pathogen DNA, ELISA detects host antibodies, and molecular probes find specific genes — all far below the threshold needed for clinical symptoms, so early diagnosis is possible.

Concept used. Biopiracy is the unauthorised commercial exploitation of biological resources (plants, animals, microbes) or traditional knowledge of indigenous communities — typically by multinational companies of developed countries — without recognition, consent, or fair compensation to the source country or community. Developing countries (rich in biodiversity and traditional knowledge but poor in legal patent infrastructure) are systematically the victims. Two landmark cases:

• 2pt
• Neem patent (W. R. Grace, USA, 1995) — patented neem's antifungal use, although Indians have used neem for centuries; eventually revoked in 2005.
• Turmeric patent (US Patent 5,401,504, granted 1995 for wound-healing) — challenged by CSIR India and revoked.
• Basmati patent (RiceTec, USA, 1997) — claimed Indian basmati varieties; most claims revoked.

1. Define biopiracy: cross-border unauthorised exploitation of bio-resources or traditional knowledge.
2. Pattern: companies from rich countries file patents on materials/uses long known in poorer countries.
3. India's response: amended its Patents Act (1970, second amendment 2002 + third amendment 2005) to prevent re-patenting of traditionally known uses; established the Traditional Knowledge Digital Library (TKDL) to provide prior-art evidence to patent offices worldwide.

Biopiracy = unauthorised use of bio-resources or traditional knowledge of developing countries by developed-country corporations. Famous examples: neem, turmeric and basmati patents — all eventually revoked after Indian challenges.

Concept used. Producing a toxin in an inactive precursor form (a protoxin or zymogen) is an evolutionary safety strategy that lets the microbe carry, store, and secrete its weapon without poisoning itself. Activation occurs only when the protoxin reaches a specific environment, such as the alkaline midgut of an insect (Bt Cry protoxin) or the acidic stomach interior for a pathogenic toxin. Outside that environment, the protoxin is inert — protecting the producer's own cellular machinery.

1. Without the protoxin mechanism, the producer cell would suffer self-toxicity (the toxin would damage its own membranes or enzymes).
2. Storing the molecule as a protoxin lets the cell accumulate large amounts safely.
3. Activation only when the protoxin enters the right host environment (alkaline gut, host protease) ensures the toxin works only on the intended target.
4. Concrete example: Bacillus thuringiensis produces Cry protoxin as crystals; the protoxin only becomes active in the alkaline midgut of caterpillars, sparing the bacterium and any non-target eaters with acidic stomachs.

Synthesising the toxin in an inactive (protoxin) form prevents self-toxicity, allows safe storage, and ensures activation only inside the target host environment.

Concept used. Conventional sexual reproduction obeys species barriers that limit gene flow to closely related organisms, building in a slow, biology-tested filter on which genes can spread. Genetic engineering bypasses these barriers, allowing genes from bacteria to enter plants, viral promoters to drive plant transcription, and so on. While powerful, this can pose long-term risks: unintended ecological consequences, allergenicity, gene flow into wild relatives (escape of transgenes), disruption of native biodiversity, and unpredictable effects on non-target organisms.

1. Allergenicity and toxicity: a transgenic protein may be a novel allergen for humans (the StarLink corn case).
2. Gene flow / escape: transgenes can introgress into wild relatives by cross-pollination, creating ``super-weeds'' or contaminating organic crops.
3. Non-target effects: Bt toxin can affect non-target beneficial insects if exposure is high.
4. Loss of biodiversity: dominance of one transgenic variety displaces traditional landraces.
5. Resistance evolution: pests evolve resistance to Bt toxins, reducing long-term effectiveness.
6. Ethical / equity concerns: corporate ownership of seeds via patents undermines farmer seed-saving traditions.

Crossing species barriers without natural checks risks allergenicity, transgene escape into wild relatives, non-target ecological harm, biodiversity loss, resistance evolution, and patent-driven inequities — long-term costs that may outweigh short-term gains.

Concept used. The second amendment to the Indian Patents Act, 1970, was cleared by Parliament in 2002 (and a third in 2005) primarily to bring India's patent regime into compliance with the WTO's TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights), and to safeguard India's biological resources and traditional knowledge against biopiracy. The amendment introduced product patents (not just process patents), explicit exclusions for traditional knowledge, mandatory disclosure of source of biological materials, and prior informed consent provisions.

1. TRIPS compliance: WTO membership obliged India to introduce product patents in pharmaceuticals and biotech by 2005.
2. Biopiracy prevention: after the neem, turmeric and basmati controversies, the law was tightened to prohibit re-patenting of traditionally known materials.
3. Disclosure: every patent applicant must disclose the geographic source of any biological material used.
4. Prior informed consent: required for use of bio-resources, in line with the Convention on Biological Diversity.

The 2002 amendment brought India into TRIPS compliance, introduced product patents in biotech and pharma, and built in safeguards against biopiracy of Indian biological resources and traditional knowledge.

Concept used. The 1997 grant of US Patent 5,663,484 to the Texas company RiceTec Inc. for ``basmati rice lines and grains'' was a clear case of biopiracy. Basmati is an aromatic long-grain rice cultivated in the Indian sub-continent (especially Punjab) for centuries and is a geographically and culturally Indian product. Granting the patent to a US company would have allowed RiceTec to claim ownership over a name, traits and grain shape that are not American innovations.

1. Basmati is a traditional Indian crop, cultivated for centuries in the Indo-Gangetic plains — it is not a US-developed novelty.
2. Indian farmers and breeders developed and refined the variety; granting the patent to a US company strips the rightful inventors of any benefit-sharing.
3. Basmati is a geographical indication (like Champagne or Darjeeling tea): the name is intrinsically tied to its region.
4. The patent would have blocked Indian exporters from using the term ``basmati'' in the US market, denting the Indian rice industry.

Basmati is a centuries-old Indian rice variety with a geographical-indication character; the inventors are Indian farmer-breeders, not American companies. A US patent would constitute biopiracy and damage Indian export rights.

Concept used. Before recombinant DNA technology, insulin was extracted from the pancreas of slaughtered cattle (bovine) and pigs (porcine). Cattle and pig insulins differ from human insulin by a few amino acids (bovine differs in 3 residues, porcine in 1). While the animal-derived hormone lowered blood glucose, it caused multiple problems.

1. Allergic reactions. The amino-acid difference made some patients mount immune responses to the foreign protein, producing rashes, swelling, or anaphylaxis.
2. Limited supply. Each pig pancreas yielded only ∼ 100 mg of insulin; meeting the growing diabetic population required millions of slaughtered animals.
3. Cost and purity. Extracting and purifying insulin from animal pancreas is expensive and the product carries contaminating proteins.
4. Religious / ethical objections. Many patients (Hindus, Muslims, vegetarians) objected to insulin sourced from cows or pigs.
5. Inconsistency. Each animal batch had slight variation in potency and contaminants.

Before rDNA, insulin was extracted from cattle and pig pancreases. Problems: allergic reactions due to amino-acid differences, limited supply, contaminants and impurities, religious objections, and inconsistent batch quality — all solved by recombinant human insulin.

Concept used. Transgenic animals carry a foreign gene introduced into their genome and expressed in their cells. By engineering animals (commonly mice) that overexpress, under-express, or carry mutant versions of human disease genes, scientists create disease models that recapitulate human pathology in a controlled, reproducible system. Such models illuminate disease mechanisms and enable preclinical drug testing.

1. Mechanism studies: a transgenic mouse expressing a human disease allele (e.g. Alzheimer's amyloid-precursor mutation) reveals how the mutation drives pathology.
2. Drug screening: candidate drugs are tested for efficacy and safety on the disease model before human trials.
3. Vaccine and therapy testing: transgenic models receive candidate vaccines or gene therapies under controlled conditions.
4. Toxicology: chemical or environmental insults are studied for long-term effects in a genetically defined animal.
5. Example: transgenic mice carrying mutant huntingtin reproduce features of Huntington's disease, allowing therapy development.

Transgenic animal models reproduce human disease in a controlled organism, letting researchers study disease mechanisms, screen drugs, test vaccines and gene therapies, and assess toxicology — accelerating biomedical discovery while reducing risk to humans.

Concept used. The first transgenic cow was Rosie, born in 1997. She was engineered to express the gene for human α-lactalbumin, a protein normally present in human milk but not in cow milk. Rosie's milk contained 2.4 g/L of human α-lactalbumin, making it nutritionally more complete than ordinary cow milk and closer in composition to human breast milk — a step toward producing infant-formula proteins via dairy cattle.

1. Name the cow: Rosie.
2. Year: 1997.
3. Gene introduced: human α-lactalbumin.
4. Purpose: enriched milk with human-type protein, suitable for infants who cannot be breast-fed.

The first transgenic cow was Rosie (1997), engineered to express the human α-lactalbumin gene, producing milk enriched with this human milk protein.

Concept used. PCR (Polymerase Chain Reaction), invented by Kary Mullis in 1983, exponentially amplifies a specific DNA segment in vitro using two primers, a thermostable DNA polymerase (Taq), dNTPs, and repeated cycles of denaturation, annealing and extension. Because PCR can amplify even a single molecule of template DNA, it can detect a pathogen long before its concentration in the blood would otherwise produce symptoms or be detectable by other tests. For RNA viruses (HIV, HCV, SARS-CoV-2), the RNA is first reverse-transcribed into cDNA (RT-PCR) before amplification.

1. Take a small clinical sample (blood, throat swab, CSF). Even a few pathogen genome copies are enough.
2. Add primers that match a unique region of the pathogen's genome.
3. Run thermal cycles: denature (95 C) → anneal (50–65 C) → extend (72 C). After n cycles, the target is amplified ∼ 2ⁿ times.
4. Detect the amplified product (gel electrophoresis, or real-time fluorescence in qPCR).
5. A positive signal confirms the pathogen's presence — often weeks before antibodies (ELISA) appear or symptoms develop.

PCR amplifies even a few copies of pathogen DNA exponentially, enabling detection long before symptoms appear or antibodies form — a key advantage for early diagnosis of infectious diseases like HIV, HCV and SARS-CoV-2.

Concept used. GEAC = Genetic Engineering Approval Committee (now Genetic Engineering Appraisal Committee in current usage), the apex regulatory body under India's Ministry of Environment, Forest and Climate Change that oversees research, development, large-scale use, and environmental release of Genetically Modified Organisms (GMOs) and recombinant DNA products. It was set up under the Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms and GMOs (1989) framed under the Environment Protection Act 1986.

1. Objective 1 — approve GMO release: evaluate biosafety dossiers for field trials, large-scale production, and commercial release of GM crops and microbes.
2. Objective 2 — biosafety oversight: monitor and regulate handling of hazardous microorganisms.
3. Objective 3 — environmental protection: minimise ecological risk from transgene escape, non-target effects, and biodiversity loss.
4. Objective 4 — public health protection: assess allergenicity, toxicity, and food safety of GM foods.
5. Objective 5 — coordinate with national bodies: work with RCGM (Review Committee on Genetic Manipulation), IBSCs (Institutional Biosafety Committees), and ICAR.

GEAC is the apex Indian regulator for GMOs and rDNA products. Its objectives: approve GM release, ensure biosafety, protect the environment, safeguard public health, and coordinate national biosafety governance.

Concept used. In 1997, the US-based company RiceTec Inc. was granted US Patent 5,663,484 for ``basmati rice lines and grains'' — claiming new rice lines with the long-grain, aromatic characteristics of traditional Indian/Pakistani basmati. India successfully challenged the patent in 2001; the US Patent Office revoked most claims, leaving only three narrow ones for specific hybrid lines.

1. Variety: Basmati rice (the aromatic long-grain rice traditionally cultivated in the Indo-Gangetic plains of India and Pakistan).
2. Company: RiceTec Inc., USA.
3. Year of patent: 1997.
4. Outcome: India's challenge (CSIR + Ministry of Commerce) led to revocation of most claims in 2001.

The patent was filed by RiceTec Inc. (USA, 1997) on Basmati rice — India successfully challenged most of the claims by 2001.

Concept used. Genetically Modified Organisms (GMOs) offer several agricultural, nutritional, medical, environmental and industrial advantages that conventional varieties cannot easily match.

1. Higher yield. Stress-tolerant crops (cold, drought, salinity, heat resistant) produce reliably on marginal land.
2. Reduced chemical input. Bt crops kill specific pests internally, cutting external pesticide use.
3. Nutritional enrichment (biofortification). Golden rice (β-carotene), iron-rich crops, high-protein varieties.
4. Longer shelf life. Flavr Savr tomato uses antisense polygalacturonase to delay ripening.
5. Disease resistance. Engineered resistance to viruses (papaya ringspot virus-resistant papaya), bacteria, fungi.
6. Medical applications. Recombinant human insulin, clotting factor VIII, vaccines, monoclonal antibodies are GMO-derived.
7. Environmental. Less reliance on chemical fertilizers, less soil and water pollution.
8. Industrial. Microbes engineered to produce biofuels, enzymes, plastics (PHA) and pharmaceuticals.

GMO advantages: higher yield, lower pesticide use, biofortification, longer shelf life, disease resistance, medical biologics (insulin, vaccines), reduced environmental damage, and industrial biotech applications.

Concept used. Gene expression — the conversion of a gene's DNA information into protein via mRNA — can be silenced or tuned down using RNA-based mechanisms. Two important methods are antisense RNA and RNA interference (RNAi). Both work by base-pairing a complementary RNA molecule to the target mRNA, either blocking its translation or marking it for degradation. The hallmark biotechnological example is RNAi-mediated silencing of a parasitic nematode gene in tobacco.

1. RNAi mechanism. Long double-stranded RNA (dsRNA) is cleaved by the enzyme Dicer into 21–23 nt small interfering RNAs (siRNA). One strand of the siRNA is loaded onto the RNA-Induced Silencing Complex (RISC, containing Argonaute). RISC uses the siRNA strand as a guide to find the complementary mRNA, which it then cleaves or blocks from translation.
2. Antisense RNA mechanism. A single-stranded RNA complementary to a target mRNA is expressed in the cell. It base-pairs with the target mRNA, forming a dsRNA that prevents ribosome binding (translational arrest) or attracts RNase H to cut the mRNA strand.
3. Example: nematode-resistant tobacco. The root-knot nematode Meloidogyne incognita infects tobacco roots. Scientists introduced into tobacco plants a transgene producing dsRNA complementary to a nematode-essential mRNA. When the nematode feeds, it ingests the siRNA, which silences its essential gene; the nematode dies, and the tobacco plant survives.

Gene expression is silenced by RNAi (dsRNA → Dicer → siRNA → RISC → mRNA cleavage) or antisense RNA (complementary RNA → ribosome blockage / RNase H cleavage). Classic example: tobacco engineered with dsRNA against the nematode Meloidogyne incognita.

Concept used. Traditional knowledge — accumulated practical wisdom of indigenous and rural communities about plants, animals and microbes — is a primary defence against biopiracy. Patent offices grant a patent only if the claimed invention is novel and non-obvious. When a use of a plant has been known for centuries to a local community, that knowledge counts as prior art and should defeat a novelty claim — provided the patent examiner has access to documented evidence of it. Ignoring traditional knowledge means failing to record and present such evidence, allowing biopirates to walk away with patents on what is essentially borrowed wisdom.

1. Neem case (1995): W. R. Grace patented neem's antifungal use, although Indians had used neem for centuries as a pesticide. The patent was revoked in 2005 after CSIR submitted ancient Sanskrit documents as prior-art evidence.
2. Turmeric case (1995): US patent for wound-healing use of turmeric was revoked after CSIR submitted ancient Ayurvedic texts establishing prior use.
3. Basmati case (1997): RiceTec's broad claims on basmati were narrowed after India submitted documentary evidence of centuries of basmati cultivation.
4. Without recorded traditional knowledge, none of these challenges would have succeeded. Hence the Traditional Knowledge Digital Library (TKDL) was set up to translate Indian medical texts into English/French/German/Japanese/Spanish for patent-office search.

Traditional knowledge serves as prior art that can defeat biopiracy patents. Ignoring or failing to document it — as before the neem, turmeric and basmati cases — costs developing countries control over their own biological heritage.

Concept used. Genetic modification of plants has produced practical advances in four major areas: pest resistance, abiotic stress tolerance, nutritional enhancement, and post-harvest quality.

1. Pest resistance. Bt cotton, Bt brinjal, Bt maize and Bt rice carry cry genes from Bacillus thuringiensis that produce insecticidal Cry proteins inside plant tissues, killing lepidopteran or coleopteran pests internally and cutting external pesticide use.
2. Abiotic stress tolerance. Engineered plants tolerate drought, salinity, cold and heat — examples include trehalose-overexpressing rice (osmoprotection) and AVP1-transgenic tomato (salt tolerance).
3. Nutritional enhancement (biofortification). Golden rice produces β-carotene in endosperm; iron-rich rice and lysine-rich maize improve micronutrient content of staples.
4. Post-harvest quality. Flavr Savr tomato uses antisense polygalacturonase mRNA to delay ripening; non-browning Arctic apples use RNAi against PPO.

Four useful areas: (i) pest resistance (Bt crops), (ii) abiotic stress tolerance (drought, salinity), (iii) biofortification (golden rice), and (iv) post-harvest quality (Flavr Savr tomato).

Concept used. A recombinant DNA vaccine is a vaccine in which the antigen is produced not by growing the actual pathogen but by cloning the antigen-encoding gene into a safe expression host (yeast, bacterium, mammalian cell, or plant), purifying the recombinant protein, and using it to immunise. The host immune system mounts an antibody response against the recombinant antigen, conferring protection without ever encountering the live pathogen. This approach is safer (no risk of accidental infection), faster (no need to culture dangerous pathogens) and produces highly pure antigens.

1. Identify the antigen-encoding gene of the pathogen (e.g. hepatitis-B surface antigen, HBsAg).
2. Clone the gene into an expression vector under a strong promoter.
3. Express the protein in a safe host (e.g. Saccharomyces cerevisiae for HBsAg).
4. Purify the recombinant antigen, formulate with adjuvant.
5. Administer to elicit an immune response.

• 2pt
• Example 1: Recombinant hepatitis-B vaccine — HBsAg expressed in Saccharomyces cerevisiae (yeast); the first commercial recombinant vaccine, approved in 1986.
• Example 2: HPV (human papillomavirus) vaccine — recombinant L1 capsid protein expressed in yeast or insect cells, self-assembling into virus-like particles.

Recombinant DNA vaccine = a vaccine made by cloning an antigen-encoding gene into a safe host (e.g. yeast) and using the purified recombinant antigen for immunisation. Examples: hepatitis-B vaccine and HPV vaccine.

Concept used. Infectious diseases are caused by an external pathogen (bacterium, virus, fungus, parasite) attacking the host; the disease can be cured by killing or eliminating the pathogen using antibiotics, antivirals, or antifungals — the patient's own genome is normal and recovers function once the pathogen is gone. Genetic diseases, in contrast, are caused by an inherent defect in the patient's own genome (a missing gene, a mutated allele); the treatment must correct or compensate for the defective gene itself, since no external agent can be killed. This is achieved by gene therapy (delivering a functional copy of the gene), enzyme replacement therapy (administering the missing enzyme), or in some cases bone-marrow transplantation.

1. Infectious disease: external pathogen → eliminate pathogen with drugs.
2. Genetic disease: defective host gene → supply functional gene (gene therapy) or supply the missing protein (enzyme replacement therapy).
3. Example: ADA-SCID — gene therapy delivers a working ADA cDNA into the patient's lymphocytes; PEG-ADA injections supply the enzyme directly.
4. Hence the lines of treatment differ fundamentally: kill an external agent vs. fix or replace a host gene/protein.

Infectious diseases are treated by eliminating the external pathogen (antibiotics, antivirals); genetic diseases are treated by correcting or compensating for the patient's own defective gene (gene therapy, enzyme replacement) since the cause is intrinsic, not external.

Concept used. A molecular probe is a short, single-stranded nucleic acid (ssDNA or ssRNA), ∼ 15–30 nt long, complementary to a target sequence and carrying a detectable label (radioactive ³²P, fluorescent dye, biotin, chemiluminescent tag). In molecular diagnostics, the probe hybridises specifically with its target sequence in the patient sample. If the target is present, the probe binds and gives a signal; if absent, no signal. This allows direct detection of disease-related DNA / RNA (e.g. a pathogen genome, a mutant oncogene, a fetal chromosomal abnormality) in clinical samples.

1. Design a probe complementary to a unique region of the target DNA (or RNA).
2. Label the probe with a detectable tag (radioactive / fluorescent / enzymatic).
3. Extract DNA / RNA from the patient sample (blood, biopsy, swab).
4. Denature the patient's DNA into single strands; hybridise with the labelled probe under stringent conditions.
5. Wash away unbound probe; visualise the bound (target-present) signal via autoradiography, fluorescence microscopy or chemiluminescent imaging.
6. Examples of probe use: FISH (Fluorescence In-Situ Hybridization) for chromosomal abnormalities (Down syndrome, BCR-ABL fusion in CML), Southern blot for genetic disorders, Northern blot for mRNA expression, microarrays for genome-wide profiling.

A labelled ssDNA / ssRNA probe hybridises with its complementary target sequence in patient DNA / RNA; the bound probe gives a detectable signal, revealing the presence or absence of the disease-associated sequence — used in FISH, Southern blot, Northern blot and microarrays.

Concept used. The first ever clinical gene-therapy patient was Ashanthi DeSilva, a 4-year-old girl with ADA-SCID, treated by W. French Anderson and Michael Blaese at the US NIH in 1990. The procedure was ex-vivo: her lymphocytes were extracted from blood, transduced with a retroviral vector carrying a functional ADA cDNA, expanded in culture, and re-infused. Because lymphocytes are short-lived (months, not decades), and because the corrected cells were mature (not hematopoietic stem cells), the procedure had to be repeated periodically to maintain therapeutic ADA levels — making the treatment recurrent.

1. Identify the patient: Ashanthi DeSilva, 1990, USA.
2. Identify the disease: ADA-SCID (genetic immunodeficiency).
3. Identify the procedure: ex-vivo retroviral delivery of ADA cDNA to lymphocytes, re-infused.
4. Explain recurrence: mature lymphocytes have a finite lifespan (∼ months); they die and are replaced by new (uncorrected) lymphocytes from bone-marrow stem cells, which still carry the ADA defect. Hence the corrected-cell pool dwindles, and treatment must be repeated.
5. Modern solution: Strimvelis (2016) targets hematopoietic stem cells, which renew the immune system permanently — a one-time treatment.

First gene-therapy patient: Ashanthi DeSilva (1990, ADA-SCID). Treatment was recurrent because only mature lymphocytes were corrected; they die naturally and are replaced by new uncorrected cells from the patient's still-defective stem cells.

Concept used. In a biotech production process, upstream processing covers everything done before the bioreactor's main fermentation — strain selection, inoculum development, medium preparation, sterilisation, optimisation of growth conditions. Downstream processing (DSP) covers everything done after fermentation — cell separation, product extraction, purification, formulation, quality control. Together they sandwich the central bioreactor step.

1. Upstream processing — example: recombinant insulin production. Strain: E. coli with the human insulin A or B chain gene. Inoculum: grown from frozen seed stock through shake flasks into a seed fermenter. Medium: defined LB or M9 with antibiotic for selection. Sterilisation: 121 C, 15 min. Conditions: temperature 37 C, pH 7.0, dissolved oxygen > 30%.
2. Fermentation. Bioreactor (5–500 L) inoculated; insulin chain accumulates as inclusion bodies inside E. coli for ∼ 8–24 h.
3. Downstream processing — example: recombinant insulin DSP. Cell harvest (centrifugation), cell lysis (homogenisation), inclusion-body isolation, refolding (oxidative disulphide formation), purification (ion exchange + size exclusion + reverse-phase chromatography), formulation (zinc-stabilised insulin solution), quality control (HPLC, mass spectrometry, biological assay), and sterile fill-and-finish.
4. Another example: penicillin DSP includes filtration, solvent extraction with butyl acetate, crystallisation, formulation into vials.

Upstream processing covers strain development, medium and inoculum preparation, and sterilisation (e.g. E. coli strain prep for recombinant insulin). Downstream processing covers cell harvest, lysis, purification (chromatography) and formulation (e.g. insulin refolding and chromatography purification).

Concept used. An antigen is any molecule (typically a protein, polysaccharide, glycoprotein, or lipid) that, when introduced into the body, triggers the immune system to produce a specific binding partner. An antibody (immunoglobulin) is a Y-shaped glycoprotein, produced by B-lymphocytes, that recognises and binds the antigen specifically through its variable-region paratopes. Antigen–antibody binding is exquisitely specific (lock-and-key), and is exploited in immunodiagnostic kits to detect either of the partners.

1. Define antigen: molecule that elicits a specific immune response and binds the resulting antibody.
2. Define antibody: Y-shaped glycoprotein from B-cells, with two antigen-binding paratopes that recognise specific epitopes.

• 2pt
• Diagnostic kit 1: ELISA (Enzyme-Linked Immunosorbent Assay) — detects HIV antibodies in serum, dengue NS1 antigen, hepatitis-B surface antigen, COVID-19 spike antibodies, allergens.
• Diagnostic kit 2: Lateral-flow immunoassay (LFA) — the home-pregnancy test (detects HCG hormone) and rapid antigen tests for malaria, HIV, COVID-19.

Antigen = molecule that triggers a specific immune response. Antibody = Y-shaped immunoglobulin from B-cells that binds the antigen. Diagnostic kits: ELISA (HIV, dengue) and lateral-flow immunoassay (pregnancy, COVID rapid tests).

Concept used. ELISA detects proteins (antigens) or anti-protein antibodies via antigen–antibody binding. Phenylketonuria (PKU) is a genetic disorder caused by a defect in the gene encoding phenylalanine hydroxylase (PAH) — the enzyme that converts phenylalanine to tyrosine. The defect leads to phenylalanine accumulation in blood, causing intellectual disability if untreated. The diagnosis of PKU requires looking at the DNA mutation or the blood phenylalanine level — neither is a classical protein–antibody pair. ELISA can therefore play only an indirect role: it can quantify blood phenylalanine (using anti-phenylalanine antibodies in a competitive ELISA) or measure PAH enzyme presence, but it cannot detect the underlying DNA mutation. Direct molecular diagnosis of PKU requires DNA-based methods (PCR + sequencing, or DNA-probe hybridisation).

1. PKU is a genetic disorder caused by DNA mutation in the PAH gene.
2. ELISA detects proteins / antibodies, not DNA mutations.
3. Hence ELISA cannot diagnose the underlying genetic defect directly.
4. For molecular diagnosis of PKU, the proper techniques are PCR-based sequencing of the PAH gene, allele-specific PCR, or DNA-probe hybridisation.
5. ELISA can serve only as a downstream protein-level test (measuring blood phenylalanine indirectly).

No — ELISA detects proteins via antigen–antibody binding, not DNA mutations. For molecular diagnosis of a genetic disorder like PKU, DNA-based methods (PCR, sequencing, DNA probes) are required. ELISA can at most measure blood phenylalanine levels indirectly.

Concept used. Mature insulin is a small hormone of ∼ 51 residues, consisting of two short polypeptide chains — A-chain (21 residues) and B-chain (30 residues) — joined by two inter-chain disulphide bridges, with one additional intra-chain disulphide within the A-chain. Its prohormone form (proinsulin) is a single polypeptide of ∼ 86 residues, in which the A and B chains are connected by an internal C-peptide (connecting peptide, ∼ 31 residues). Conversion of proinsulin to insulin requires proteolytic excision of the C-peptide.

1. Number of chains: proinsulin = one continuous chain (A–C–B); mature insulin = two separate chains (A + B) held by disulphide bridges.
2. Length: proinsulin ∼ 86 aa; mature insulin ∼ 51 aa (A 21 + B 30).
3. Presence of C-peptide: present in proinsulin, absent in mature insulin.
4. Biological activity: proinsulin is inactive; mature insulin is the active hormone.
5. Maturation step: prohormone-convertase enzymes (PC1, PC2 and carboxypeptidase E) cleave out the C-peptide in the secretory granules of pancreatic β-cells.

Proinsulin is a single 86-residue inactive precursor with A–C–B chain layout (C = C-peptide); mature insulin is the 51-residue active hormone (A + B chains joined by disulphide bridges) generated by proteolytic excision of the C-peptide.

Concept used. Both gene therapy (introducing a functional gene) and enzyme replacement therapy (ERT) (administering the functional protein/enzyme) aim to restore function lost due to a genetic defect. They differ in durability, cost, complexity, and the underlying logic of treatment.

1. Enzyme replacement therapy:
   • 2pt
   • Pros: relatively simple — administer purified enzyme intravenously; predictable dosing; no genome alteration.
   • Cons: lifelong, expensive, repeated injections required; can trigger antibody response against the recombinant enzyme over time.
2. Gene therapy:
   • 2pt
   • Pros: one-time / few treatments (if targeted at stem cells), potentially permanent cure, no recurring cost after initial treatment.
   • Cons: requires vector development, regulatory clearance, ex-vivo cell manipulation; risk of insertional mutagenesis (vector integration disturbing host genes); not yet possible for every disease.
3. Overall verdict: gene therapy is the better long-term option for genetic disorders because it tackles the root cause — the defective gene — and offers a potential permanent cure with a single treatment (especially when stem cells are targeted, as in modern Strimvelis for ADA-SCID).

Gene therapy is the better long-term option: it addresses the root cause (defective gene) and can provide a permanent cure with a single treatment, whereas enzyme replacement therapy requires lifelong injections and can trigger immune reactions. ERT is, however, currently more widely available and easier to administer.

Concept used. Transgenic animals are organisms whose germ-line cells stably carry one or more foreign genes (transgenes), often inserted by microinjection into a zygote or via embryonic-stem-cell engineering. They serve two broad purposes: basic research (understanding biological processes by tracking the foreign gene's product) and biotechnology production (using the animal as a bioreactor for a useful protein).

1. Example of fundamental research: Transgenic mice expressing mutant human amyloid-precursor protein (APP) — a model for Alzheimer's disease that reveals how amyloid plaques form, allowing study of the basic pathology and screening of candidate drugs.
2. Example of useful product: Rosie, the first transgenic cow (1997) — engineered to produce human α-lactalbumin in her milk, a nutritionally important protein for infant formula.
3. Other useful-product examples: transgenic goats producing human anti-thrombin in milk (FDA-approved as ATryn, 2009); transgenic sheep producing α-1 antitrypsin in milk for AAT-deficiency emphysema.

Fundamental research example: transgenic mice with mutant human APP gene (Alzheimer's model). Useful-product example: Rosie the transgenic cow (1997) producing human α-lactalbumin in milk.

Concept used. Foreign DNA (a transgene) introduced into a host cell is maintained either by stable integration into the host chromosome (so that every round of host DNA replication automatically copies the transgene) or by episomal replication on an autonomous vector (a plasmid with its own origin of replication). It is transferred to progeny only if it is present in the germ cells / hereditary material — that is, if the transgene either integrates into a chromosome of a germ-line cell or sits on an episome that is reliably partitioned during cell division.

1. Maintenance in the host:
   • 2pt
   • Integration: the transgene physically joins a host chromosome (e.g. retroviral integration, T-DNA integration in plants). Once integrated, it replicates with the host DNA every cell cycle.
   • Episome: the transgene sits on an autonomous plasmid with its own ori (e.g. in bacteria) and replicates each cell cycle.
2. Inheritance to progeny:
   • 2pt
   • In sexually reproducing animals: the transgene is inherited only if introduced into the zygote or germ cells (pronuclear microinjection of fertilised eggs).
   • In plants: the transgene must integrate into the plant chromosome before regeneration into a whole plant, so all seeds carry it.
   • In bacteria: the transgene plasmid is partitioned into daughter cells during binary fission; if stable, it persists.
3. Selection: antibiotic-resistance or reporter markers in the transgene let researchers select cells that retain it.

Foreign DNA is maintained either by integrating into a host chromosome (replicating with it) or by sitting on an autonomous episome with its own origin. It is transferred to progeny only if present in germ-line cells / hereditary material — through germ-line integration in animals, chromosomal integration in plants, or stable plasmid partitioning in bacteria.

Concept used. The Cry proteins of Bacillus thuringiensis are a family with strict host specificity: each Cry protein binds a specific receptor on the midgut cells of a narrow taxonomic group. Cry1A proteins bind receptors of lepidopterans (moths, butterflies); Cry2A extends to some lepidopterans and dipterans (flies, mosquitoes); Cry3A is active against coleopterans (beetles). No single Cry protein covers all pest groups. Hence Bt cotton expressing cry1Ac (the most common commercial gene) is highly effective against lepidopteran bollworms but is not resistant to other pests such as sap-sucking insects (aphids, whiteflies, jassids), mites, nematodes, plant viruses, fungi or weeds.

1. Bt cotton typically expresses Cry1Ac (and increasingly Cry2Ab) — targeting lepidopteran caterpillars.
2. Sap-sucking pests (aphids, whiteflies, jassids) have a piercing-sucking mouth and do not ingest leaf tissue — they are not killed by Bt.
3. Mites, nematodes, fungi, viruses, weeds: completely outside the Cry-protein target spectrum.
4. Hence Bt cotton still requires fungicide, herbicide and miticide sprays.

No. Bt cotton's Cry proteins are taxonomically specific — typically active against lepidopteran bollworms (Cry1Ac) only, not against sap-sucking pests, mites, nematodes, fungi, viruses or weeds, which still require conventional control.

Concept used. ADA deficiency is a rare autosomal recessive genetic disorder in which the patient lacks a functional adenosine deaminase (ADA) enzyme. Without ADA, toxic deoxyadenosine accumulates in lymphocytes, killing them and producing Severe Combined Immunodeficiency (SCID) — a profound loss of B- and T-cell immunity. Affected children cannot fight even routine infections and historically had to live inside sterile plastic bubbles. Today, three treatments are available, with gene therapy offering the most definitive cure.

1. Step 1 — Diagnosis. Suspect ADA-SCID in infants with recurrent infections from the first weeks of life; confirm by enzyme assay (low/no ADA in erythrocytes) and DNA sequencing of the ADA gene on chromosome 20.
2. Step 2 — Bone-marrow transplantation (BMT). A matched-sibling bone-marrow transplant can fully reconstitute the immune system. This is the first-line cure if a matched donor exists. Limitation: most patients lack a matched donor.
3. Step 3 — Enzyme replacement therapy (ERT) — PEG-ADA. Polyethylene-glycol-modified bovine ADA (Adagen / PEG-ADA) is injected intramuscularly once or twice a week. PEG conjugation prolongs the enzyme's half-life and reduces immunogenicity. It restores ADA activity in plasma but the patient must continue injections lifelong; cost is very high.
4. Step 4 — Gene therapy. The definitive cure. Two approaches: (i) Mature lymphocyte gene therapy (original 1990 Ashanthi DeSilva protocol). Patient lymphocytes are extracted, transduced ex-vivo with a retroviral vector carrying a functional ADA cDNA, expanded in culture, and re-infused. Recurrent treatments are needed because lymphocytes die naturally over months. (ii) Hematopoietic stem-cell gene therapy (modern Strimvelis, EMA-approved 2016). Patient's own CD34+ stem cells are extracted from bone marrow, transduced ex-vivo with a lentiviral / retroviral vector carrying ADA cDNA, and re-infused after mild conditioning. Because stem cells continuously produce new lymphocytes, a single treatment provides life-long correction.
5. Step 5 — Earliest intervention. Treatment should start as early as possible (ideally within the first months of life), before recurrent infections damage organs.

Yes — ADA deficiency can be cured. Three options: (i) matched-sibling bone-marrow transplantation (if a donor exists), (ii) PEG-ADA enzyme replacement therapy (life-long injections), (iii) gene therapy. The modern stem-cell gene therapy (Strimvelis) is the definitive single-shot cure: patient hematopoietic stem cells are transduced ex-vivo with a viral vector carrying a working ADA gene and re-infused.

Concept used. Transgenic animals are animals whose genome has been deliberately altered by stable integration of a foreign gene (transgene), typically by pronuclear microinjection into a fertilised egg, retroviral infection of early embryos, or genome editing of embryonic stem cells. The transgene is inherited by all somatic and germ cells of the resulting animal, and by its progeny. Transgenic animals (most commonly mice, but also rats, rabbits, pigs, sheep, goats, cattle and fish) serve four major roles: studying normal gene function, modelling human disease, producing useful biological products (molecular farming), and testing the safety of vaccines and drugs.

1. Area 1 — Normal physiology and development. Transgenic mice expressing or knocking out a specific gene reveal what that gene does. Examples: targeted knockout of Hox genes shows their role in axial patterning; overexpression of growth-factor genes reveals their role in tissue growth. This is the basic-research workhorse.
2. Area 2 — Studying human diseases. Transgenic animals carrying mutant human disease genes recreate the disease in a controlled organism. Examples include the Alzheimer's mouse (mutant APP gene producing amyloid plaques), Huntington's mouse (mutant huntingtin gene producing motor and cognitive defects), cystic-fibrosis mouse (CFTR knockout), cancer mice (oncogene activation). These models let researchers track disease progression and screen candidate drugs before human trials.
3. Area 3 — Biological products (molecular farming). Transgenic livestock are engineered to secrete a valuable human protein in their milk (an organ that produces large amounts of protein cheaply and recoverably). Examples: Rosie the cow (1997) producing human α-lactalbumin; transgenic goats producing human anti-thrombin (ATryn, FDA-approved 2009); transgenic sheep producing human α-1-antitrypsin (for emphysema). These animals act as biological factories for human therapeutics.
4. Area 4 — Vaccine and chemical safety testing. Transgenic mice carrying human immune-system components are used to test the safety and immunogenicity of new vaccines before human trials. Transgenic mice expressing human metabolic genes are used to test the toxicity of new chemicals on a system that mimics human metabolism — providing more reliable predictions than non-transgenic animals.

Transgenic animals carry stably integrated foreign genes. Four areas of use: (i) study normal gene function (mouse knockouts), (ii) model human disease (Alzheimer's, Huntington's, cancer mice), (iii) molecular farming — produce useful proteins in livestock milk (Rosie the cow, ATryn goats), and (iv) test vaccine and chemical safety (humanised mice as predictive models).

Concept used. Transferring a bacterial gene to a plant requires (i) isolating the bacterial gene, (ii) cloning it into a suitable plant-expression vector, (iii) introducing the vector into plant cells, (iv) selecting and regenerating the transgenic plant, and (v) confirming transgene expression and inheritance. The standard plant-transformation system is the Ti plasmid of Agrobacterium tumefaciens (for dicots) or particle bombardment (for monocots).

1. Step 1 — Isolate the bacterial gene. Extract bacterial DNA. PCR-amplify the target gene using gene-specific primers, or cut total DNA with restriction enzymes and clone fragments to identify the gene.
2. Step 2 — Clone the gene into a plant-expression cassette. Insert the gene downstream of a strong plant promoter (commonly CaMV 35S) and upstream of a polyadenylation signal (nos terminator). Include a selectable marker (e.g. nptII for kanamycin resistance) in a binary vector.
3. Step 3 — Transform Agrobacterium tumefaciens. Move the binary vector into a disarmed Agrobacterium strain whose Ti plasmid retains vir genes but lacks the tumour-inducing genes — so it can deliver T-DNA without forming a tumour.
4. Step 4 — Co-cultivate Agrobacterium with plant tissue. Wound a plant explant (leaf disc) and co-cultivate with the engineered Agrobacterium. The bacterium delivers the T-DNA (carrying your gene + marker) into plant nuclei, where it integrates into a plant chromosome.
5. Step 5 — Select transformed cells. Transfer explants to selection medium (kanamycin or similar). Only transformed cells (with nptII) survive and form callus.
6. Step 6 — Regenerate transgenic plants. Induce shoot and root differentiation on plant hormones, then transfer to soil. The result is a whole transgenic plant carrying the bacterial gene.
7. Step 7 — Confirm transgene integration and expression. Use PCR (confirms integration), Southern blot (confirms genomic integration), Northern blot (confirms mRNA expression), and Western blot or enzyme assay (confirms protein production).
8. Step 8 — Test inheritance. Allow the transgenic plant to set seed; check the next generation for transgene inheritance and stable expression.

Flow-chart form:

Steps: isolate the bacterial gene by PCR; clone into a binary vector with CaMV 35S promoter and selectable marker; transform disarmed Agrobacterium tumefaciens; co-cultivate with plant leaf-disc explant; select on antibiotic medium; regenerate transgenic plants; confirm transgene by PCR / Southern / Western blot; test inheritance in next-generation seeds.

Concept used. Biotechnology — the application of biological systems and recombinant DNA technology for useful products and services — has reshaped five major areas of modern life: medicine, agriculture, environment, food and beverages, and industry.

1. Medicine. Recombinant therapeutic proteins (human insulin, growth hormone, clotting factor VIII, α-1 antitrypsin); recombinant vaccines (hepatitis B, HPV); monoclonal antibodies for cancer and autoimmune disease (Herceptin, rituximab); gene therapy (Strimvelis for ADA-SCID, Luxturna for retinal dystrophy); molecular diagnostics (PCR, ELISA, microarrays).
2. Agriculture. GM crops with pest resistance (Bt cotton, Bt brinjal), herbicide tolerance (Roundup Ready soy), biofortification (golden rice), stress tolerance (drought / salt tolerant rice); transgenic livestock (Rosie cow).
3. Environment. Bioremediation using engineered microbes to degrade oil spills (Pseudomonas putida, the famous ``super-bug''), pesticides, plastics, heavy metals; biofuels (ethanol, biodiesel) from engineered yeast / algae; biosensors for pollutant monitoring.
4. Food and beverages. GM enzymes used in food processing (recombinant chymosin for cheese replacing animal rennet); GM crops with improved nutrition (golden rice) or shelf life (Flavr Savr tomato); microbial production of food additives (citric acid, MSG, vitamins).
5. Industry. Microbial production of bulk and specialty chemicals (insulin, ethanol, citric acid, amino acids, antibiotics, enzymes such as proteases for detergents, cellulases for textile processing); bioplastics (PHA, PLA); enzyme-based biofuels.

Five areas: (i) Medicine — recombinant drugs, vaccines, gene therapy, diagnostics. (ii) Agriculture — Bt crops, golden rice, transgenic livestock. (iii) Environment — bioremediation, biofuels. (iv) Food and beverages — recombinant chymosin, biofortified crops. (v) Industry — microbial production of chemicals, enzymes, bioplastics.

Concept used. GM crops can boost yield not by directly making plants grow faster but by reducing the major losses that plague conventional agriculture — losses from pests, diseases, weeds, abiotic stress, and post-harvest spoilage — and by enhancing nutritional value, so that each plant yields more usable food.

1. Pest resistance. Bt crops (cotton, brinjal, maize, rice) carry the cry gene from Bacillus thuringiensis, producing Cry proteins that kill caterpillar pests internally. This reduces pest damage by ∼ 50% in cotton, raising effective yield.
2. Abiotic stress tolerance. Engineered tolerance to drought, salinity, cold and heat allows reliable yields on marginal land where conventional crops would fail (e.g. trehalose-overexpressing rice for drought, AVP1 transgenic tomato for salt).
3. Herbicide tolerance. Roundup Ready crops (soy, maize, cotton) tolerate glyphosate; farmers spray the herbicide post-emergence, killing weeds without harming the crop — eliminating yield loss from weed competition.
4. Disease resistance. Engineered resistance to viral, bacterial and fungal pathogens (e.g. papaya ringspot virus-resistant papaya in Hawaii) protects against yield-destroying outbreaks.
5. Reduced post-harvest loss. Flavr Savr tomato (delayed-ripening antisense) and non-browning Arctic apples (RNAi against PPO) extend shelf life, reducing post-harvest spoilage.
6. Biofortification. Golden rice (β-carotene), iron-rich rice, lysine-rich maize — these improve the nutritional yield per kilogram of grain.
7. Reduced chemical inputs. Lower pesticide / fertilizer use cuts production cost and environmental damage, indirectly raising farmer profit per unit yield.
8. Faster generation of new varieties. Direct gene insertion produces new traits in 2–3 years vs. 8–10 years for conventional breeding — accelerating yield improvements.

GM plants raise yield by reducing pest, disease, weed and stress losses (Bt crops, stress-tolerant crops, herbicide-tolerant crops, virus-resistant crops), extending shelf life (Flavr Savr), boosting nutritional yield (golden rice), cutting input costs, and accelerating new-variety development.

Concept used. GM plants reduce pesticide use by engineering pest-resistance traits directly into the plant tissue (so external sprays become unnecessary), and enhance nutritional value by engineering biosynthesis pathways for missing vitamins or minerals into the edible parts of the plant (biofortification).

1. (a) Reducing chemical pesticide use — example: Bt cotton. Conventional cotton requires repeated spraying of broad-spectrum insecticides (organochlorines, pyrethroids) to control bollworm (Helicoverpa armigera, Pectinophora gossypiella). These sprays pollute water, kill non-target insects, and expose farm workers to toxic chemicals. Bt cotton carries the cry1Ac gene from Bacillus thuringiensis, producing the Cry1Ac protein in plant tissues. When a bollworm caterpillar eats a Bt-cotton leaf, the Cry1Ac protoxin is solubilised in the larva's alkaline midgut, activated by gut proteases, and binds receptors on midgut epithelial cells — forming pores that lyse the cells and kill the larva. Because the toxin is made by the plant itself, no external insecticide spray is needed for bollworm control. In India, Bt-cotton adoption reduced bollworm-targeted pesticide sprays by 50–80%, lowering farmer health risk, cutting input cost, and reducing environmental pollution.
2. (b) Enhancing nutritional value — example: Golden rice. Vitamin-A deficiency (VAD) is the leading cause of childhood blindness in rice-staple countries (South / South-East Asia, Africa) — hundreds of thousands of children go blind or die from immune impairment each year. Normal rice endosperm cannot make β-carotene (the dietary precursor of vitamin A). Golden rice was engineered by Ingo Potrykus and Peter Beyer (2000) to express two genes in the rice endosperm: psy (phytoene synthase, from daffodil and later maize) and crtI (carotene desaturase, from Erwinia uredovora). Together, these genes complete the β-carotene biosynthetic pathway in endosperm, giving the grain its characteristic yellow ``golden'' colour. Children eating golden rice receive sufficient dietary β-carotene to meet vitamin-A requirements, directly addressing VAD without changing the staple food.

(a) Bt cotton expresses bacterial Cry1Ac protein that internally kills bollworms, eliminating 50–80% of insecticide sprays. (b) Golden rice expresses psy + crtI genes to make β-carotene in endosperm, addressing vitamin-A deficiency in rice-staple populations.

Concept used. Pre-recombinant insulin was extracted from the pancreas of slaughtered cattle (bovine) and pigs (porcine). Although it lowered blood glucose, it suffered from multiple disadvantages that recombinant human insulin was designed to overcome.

1. Immunogenic / allergic reactions. Bovine insulin differs from human insulin by three amino acid residues; porcine insulin by one. The foreign sequence often triggered host immune reactions ranging from local rashes to systemic anaphylaxis, and longer-term antibody formation reduced therapeutic efficacy.
2. Limited supply. Each pig pancreas yields only ∼ 100 mg of insulin. Meeting a growing diabetic population would require millions of animals — slaughter capacity could not keep up with demand.
3. High cost and impurity. Extraction and purification from animal pancreas were expensive; even purified preparations carried trace contaminants (other pancreatic proteins, glucagon, proinsulin) that contributed to immune reactions.
4. Religious and ethical objections. Many Hindus, Muslims, vegetarians, and some Christians objected to insulin from cattle or pigs, leaving devout patients without an acceptable treatment option.
5. Batch-to-batch variability. Each animal batch differed slightly in potency and contaminant profile, making dose standardisation imperfect.
6. Risk of zoonotic contamination. Animal-derived biological products carried a small but real risk of transmitting unknown animal pathogens (analogous to the prion-disease concerns that emerged for bovine-derived medicines later).
7. Cattle / pig welfare and supply ethics. The therapy depended on continuous animal slaughter, raising additional ethical concerns.

Animal-derived insulin caused immune / allergic reactions (sequence mismatch), suffered from supply shortage (each pig pancreas → 100 mg), was costly and impure, drew religious / ethical objection, varied batch-to-batch, and carried zoonotic contamination risk — all eliminated by recombinant human insulin.

Concept used. Recombinant human insulin (e.g. Humulin, Eli Lilly 1982) is produced by inserting the human insulin A and B chain genes into Escherichia coli (separately, as inclusion bodies), expressing the chains, extracting and refolding them, and chemically linking them via disulphide bridges. The resulting product is structurally identical to natural human insulin, free of animal-source contaminants, and producible in unlimited quantities — addressing every drawback of animal-derived insulin.

1. Identical to human insulin. Recombinant insulin has the human amino-acid sequence; immune reactions are essentially eliminated.
2. Unlimited supply. E. coli can be scaled up indefinitely in bioreactors; production capacity is no longer tied to animal-slaughter rate.
3. High purity. Multi-step chromatography produces insulin of pharmaceutical-grade purity (> 99%), free of animal contaminants.
4. Cost-effective at scale. Once the production process is established, microbial fermentation is far cheaper than extracting insulin from animal pancreas.
5. No religious / ethical issues. The bacterial source is acceptable to Hindus, Muslims, vegetarians, and others.
6. Consistent batches. Defined fermentation conditions and purification protocols give highly reproducible product quality.
7. No zoonotic risk. Bacterial production eliminates the risk of transferring animal-borne pathogens.
8. Enables analogue insulins. The same recombinant technology produces engineered analogues with modified pharmacokinetics (rapid-acting lispro / aspart; long-acting glargine / detemir) — impossible with animal-derived insulin.

Recombinant human insulin: structurally identical to human insulin (no allergies), unlimited supply, high purity, lower cost at scale, no religious/ethical issues, consistent batches, no zoonotic risk, and enables engineered insulin analogues — addressing every animal-insulin drawback.

Concept used. A biopesticide is a pest-control agent derived from a living organism — typically a bacterium, virus, fungus, plant or insect-predator — used to suppress pests in place of, or alongside, chemical pesticides. Biopesticides are usually highly target-specific, biodegradable, and environmentally safer than broad-spectrum chemical pesticides. The most popular biopesticide globally is the bacterium Bacillus thuringiensis (Bt).

1. Definition. Biopesticide = pesticide derived from a biological source. Categories include microbial pesticides (Bt, NPVs, Trichoderma), plant-incorporated protectants (Bt crops), and biochemical pesticides (pheromones, plant extracts).
2. Most popular example: Bacillus thuringiensis (Bt). A Gram-positive, spore-forming soil bacterium that produces crystalline protein toxins (Cry proteins) during sporulation. Available commercially as wettable powder, granular formulation, or expressed inside transgenic plants.
3. Mode of action. (i) The Cry protein is synthesised as an inactive crystal protoxin during bacterial sporulation. (ii) When a susceptible insect larva ingests Bt spray (or eats a Bt-engineered plant leaf), the protoxin enters the larva's midgut. (iii) The alkaline pH (9–10.5) of the lepidopteran midgut solubilises the crystal. (iv) Midgut proteases cleave the protoxin into the smaller, active Cry toxin. (v) The active Cry toxin binds specific receptors (e.g. cadherin-like proteins) on midgut epithelial cells. (vi) Bound toxin inserts into the cell membrane and oligomerises to form pores. (vii) Pore formation disrupts the osmotic balance, lysing the midgut epithelial cells. (viii) The larva stops feeding, the gut contents leak into the haemocoel, septicaemia develops, and the larva dies within 1–3 days.
4. Selectivity. Different Cry proteins are active against specific insect orders — Cry1A on lepidopterans (moths, butterflies), Cry2A on lepidopterans / dipterans, Cry3A on coleopterans (beetles). Mammals, birds, fish, and beneficial insects (bees, ladybugs) lack the receptors and are unaffected — making Bt extraordinarily safe.
5. Application examples. Bt sprays on cabbage, tomato, vegetables; Bt-engineered cotton (Bt cotton), maize, brinjal; mosquito-control Bacillus thuringiensis var. israelensis (Bti) in stagnant water.

A biopesticide is a living-source pest-control agent. The most popular example is Bacillus thuringiensis (Bt). Mode of action: ingested Cry protoxin is solubilised and activated in the insect's alkaline midgut, binds gut-cell receptors, forms membrane pores, lyses gut cells, and kills the larva within days — with strict species selectivity sparing mammals and beneficial insects.

Concept used. Recombinant DNA technology requires five molecular-biology tools that, between them, let researchers cut, join, copy, deliver, and select specific DNA sequences across organisms.

1. Tool 1 — Restriction enzymes (molecular scissors). Site-specific endonucleases (e.g. EcoRI, BamHI, HindIII) that recognise 4–8 bp palindromic sequences and cut both strands, often producing sticky ends that aid ligation. Function: precisely cut DNA at defined sequences to release a gene of interest from one source and prepare a vector for insertion.
2. Tool 2 — DNA ligase (molecular glue). T4 DNA ligase joins two DNA fragments by forming a phosphodiester bond between adjacent 3^′-OH and 5^′-phosphate groups. Function: seal the gene of interest into the cut vector, creating a recombinant DNA molecule.
3. Tool 3 — Cloning vectors (DNA vehicles). Self-replicating DNA molecules (plasmids like pBR322, pUC19; bacteriophages; cosmids; YACs; BACs; Agrobacterium Ti plasmid for plants) that carry an origin of replication (ori), selectable marker (antibiotic resistance), and unique restriction sites for insertion. Function: deliver the recombinant DNA into a host cell and allow it to replicate.
4. Tool 4 — Host organism (cellular factory). Living cells (E. coli most common, also Saccharomyces cerevisiae, mammalian CHO cells, plant cells) that take up the vector and express the cloned gene. Function: replicate the recombinant DNA and produce the encoded protein in useful amounts.
5. Tool 5 — DNA polymerase / PCR (molecular amplifier). Thermostable Taq DNA polymerase used in PCR (Polymerase Chain Reaction) to amplify a specific DNA segment exponentially using two primers and 25–40 thermal cycles. Function: amplify the gene of interest from a tiny starting amount to quantities sufficient for cloning, sequencing or diagnostic detection.

The standard rDNA workflow combines all five: PCR amplifies the gene → restriction enzymes cut both gene and vector → ligase joins them → vector + recombinant DNA enters host → host produces protein.

Five key tools of rDNA technology: (i) restriction enzymes (cut DNA at specific sites), (ii) DNA ligase (joins DNA fragments), (iii) cloning vectors (deliver and replicate recombinant DNA in host), (iv) host organism (replicates the construct and produces the protein), and (v) DNA polymerase / PCR (amplifies specific DNA segments).